EJNMMI reports最新文献

{"title":"18F-FDG versus 18F-FDOPA PET in recurrent medulloblastoma: a case study and literature review.","authors":"Abarnaa Sivapathasundaram, Florence Laigle-Donadey, Catherine Horodyckid, Karima Mokhtari, Aurélie Kas, Laura Rozenblum","doi":"10.1186/s41824-025-00271-7","DOIUrl":"10.1186/s41824-025-00271-7","url":null,"abstract":"<p><p>Medulloblastoma is a heterogeneous central nervous system tumor stratified into four molecular subgroups in the revised 2021 WHO classification. Although MRI remains essential for follow-up, distinguishing true recurrence from treatment-related changes can be challenging. PET imaging may provide additional value in this context; however, evidence in medulloblastoma is limited to small series and case reports, with most available PET data originating from glioma studies. Here, we report a medulloblastoma patient experiencing two recurrences assessed sequentially with 18F-FDOPA and 18F-FDG PET imaging. This case highlights considerations in PET tracer selection, aiming to support clinical decision-making and enhance diagnostic accuracy for physicians managing recurrent medulloblastoma.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"39"},"PeriodicalIF":0.0,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12612431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145508612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular imaging in the diagnostic process of neuroendocrine tumors: a systematic review on unknown primary origin and suspected NETs.","authors":"Laura Alonzo, Roberto Cannella, Riccardo Laudicella, Viviana Benfante, Pierpaolo Purpura, Giuseppe Micci, Massimo Galia, Giuseppe Brancatelli, Massimo Midiri, Pierpaolo Alongi","doi":"10.1186/s41824-025-00274-4","DOIUrl":"10.1186/s41824-025-00274-4","url":null,"abstract":"<p><strong>Background: </strong>Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms often arising in the gastrointestinal tract, pancreas, and lungs. Diagnosing NETs can be challenging due to their small size, slow growth, and low metabolic activity, especially in cases of unknown primary origin (CUP-NETs). Timely identification of the primary lesion is critical for tailored treatment planning, including peptide receptor radionuclide therapy (PRRT), surgery, or somatostatin analogue administration.</p><p><strong>Objective: </strong>This systematic review evaluates the diagnostic performance and clinical impact of molecular imaging-especially PET/CT with radiolabeled somatostatin analogs-in patients with suspected NETs or CUP-NETs.</p><p><strong>Methods: </strong>Following PRISMA guidelines, a comprehensive literature search was conducted in PubMed and Scopus. Data on study design, tracers used, detection rates, and impact on patient management were extracted. Quality assessment was performed using CASP tools.</p><p><strong>Results: </strong>PET/CT using [68 Ga]Ga-DOTA-peptides (DOTATATE, DOTATOC, DOTANOC) consistently outperformed conventional SPECT imaging with [111In]Pentetreotide (Octreoscan), achieving primary tumor detection rates of 38%-83% versus < 10% with SPECT. In suspected NETs, PET/CT demonstrated high sensitivity (up to 95%) and specificity ( > 85%), with changes in clinical management reported in up to 33% of cases. Dual-tracer imaging ([68 Ga]Ga-DOTATATE and [18F]FDG) and newer tracers such as [18F]DOPA and [18F]AlF-NOTA-octreotide ([18F]-OC) provided added diagnostic value, particularly in aggressive or rare subtypes (e.g. paragangliomas, insulinomas). Detection of unknown primaries commonly led to curative surgical options or more targeted therapies.</p><p><strong>Conclusions: </strong>Molecular imaging-particularly [⁶⁸Ga]Ga-DOTA-peptide PET/CT-represents an essential component in the diagnostic evaluation of undefined/suspected NETs. It not only improves diagnostic accuracy but also has a profound impact on clinical decision-making. Its integration into diagnostic algorithms should be strongly considered for both known and suspected cases of neuroendocrine neoplasia.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"38"},"PeriodicalIF":0.0,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12589696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145454523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of different lymph node metastases delineation approaches in [¹⁸F]SiTATE PET/CT imaging in NET patients.","authors":"Sophie Carina Siegmund, Magdalena Schöll, Vera U Wenter, Gabriel T Sheikh, Maximilian Scheifele, Franz Josef Gildehaus, Simon Lindner, Lalith K Shiyam Sundar, Christine Spitzweg, Christoph J Auernhammer, Rudolf A Werner, Mathias J Zacherl","doi":"10.1186/s41824-025-00273-5","DOIUrl":"10.1186/s41824-025-00273-5","url":null,"abstract":"<p><strong>Background: </strong>Accurate tumor delineation in somatostatin receptor (SSTR) PET/CT is imperative for quantifying tumor burden, therapy monitoring, and response assessment in gastroenteropancreatic neuroendocrine tumors (GEPNETs). This study aimed to evaluate different SSTR PET-based tumor delineation approaches, based on a lymph node metastasis as reference standard, and determine the most robust method for volume assessment. Singular, non-bulky lymph node metastases with a short axis diameter ≥ 1.0 cm from [¹⁸F]SiTATE PET/CT scans were included. Different tumor delineation methods were applied: fixed SUV thresholds, isocontours relative to SUV_max, and individual backwards thresholding. The correlation between PET-derived volumes and CT-derived volumes (reference standard) were investigated.</p><p><strong>Results: </strong>An isocontour approach using 45% of SUV_max demonstrated the strongest correlation with CT-derived volumes (r = 0.874; r² = 0.764; p < 0.001), outperforming fixed SUV thresholds, e.g. SUV 4.0 (r = 0.727; r² = 0.529; p < 0.001). The application of a backwards threshold approach resulted in the identification of significant variability (CoV: 59.6% for fixed SUV, 31.3% for isocontour).</p><p><strong>Conclusion: </strong>The 45% isocontour-thresholding relative to lesional SUV_max approach constitutes a robust and clinically applicable method for SSTR PET-based tumor delineation in GEPNET patients, irrespective of changes of SSTR avidity of reference tissues (e.g. liver). Further validation is required to establish its role in total tumor volume assessment and therapy monitoring.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"37"},"PeriodicalIF":0.0,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12572447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145403593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous dual-isotope SPECT imaging using a cardiac cadmium-zinc-telluride camera with various Technetium-99 m to Iodine-123 ratios.","authors":"Takayuki Shibutani, Masahisa Onoguchi, Hiroto Yoneyama, Takahiro Konishi, Kenichi Nakajima","doi":"10.1186/s41824-025-00272-6","DOIUrl":"10.1186/s41824-025-00272-6","url":null,"abstract":"<p><strong>Objective: </strong>Cadmium-zinc-telluride (CZT) SPECT cameras offer high energy resolution. This allows simultaneous dual-isotope (SDI) acquisition even when ¹²³I and ^99mTc photon peaks are close. This study aimed to reveal the impact of image quality for ^99mTc/¹²³I ratios on SDI images.</p><p><strong>Methods: </strong>We created normal and inferior wall defect myocardial models using an anthropomorphic myocardial phantom. The doses of ^99mTc/¹²³I ratios were set to 1.0, 3.5, 5.0 and 6.5 (referred to as Tc/I_1.0, Tc/I_3.5, Tc/I_5.0 and Tc/I_6.5 conditions). We acquired SPECT images using D-SPECT Cardio. The acquisition time was adjusted to achieve 1.5 × 10⁶ left ventricular ¹²³I counts as a clinical reference. Short-axis images were reconstructed with (SC) and without (NC) scatter correction. Kernel and Gaussian-standard values were set to 1 and 1.0 as default conditions. The filter parameters were changed to 1, 3 and 5 for the kernel settings, and 0.25-1.0 for Gaussian standards. The image quality of normal and defective myocardia at different ^99mTc/¹²³I ratios was evaluated as cavity contrast on short-axis images, the percent coefficient of variance (%CV) and %uptake on polar maps. In addition, these reconstruction conditions were applied to a patient with acute coronary syndrome, supporting the phantom-based findings.</p><p><strong>Results: </strong>In the normal myocardial phantom, %uptake in the inferior and inferolateral myocardial walls was significantly lower in SC images than in NC images for both ^99mTc and ¹²³I. In SC images, ^99mTc counts in the inferoseptal myocardial wall slightly decreased along with the ^99mTc/¹²³I ratio, whereas ¹²³I counts in the inferolateral walls declined as the ^99mTc/¹²³I ratio increased to 6.5. Higher kernel and Gaussian standard settings resulted in lower %CV values in both NC and SC ^99mTc and ¹²³I images, improving image uniformity. Overall, NC images showed more homogeneous myocardial distribution in the inferior wall compared with SC images.</p><p><strong>Conclusion: </strong>Image quality and correction effects are influenced by ^99mTc/¹²³I ratios, resulting in heterogeneity in the inferior wall of the normal myocardium due to SC. Adjusting kernel parameters of the Gaussian filter or using NC images may help improve image quality when ^99mTc/¹²³I ratios are very high or low.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"36"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12535947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145331391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of suspicious prostate lesions at multiparametric MRI with dynamic ⁶⁸ Ga-Gozetotide PET/CT.","authors":"Daniel Parrott, Qing Yuan, Daniella Pinho, Yin Xi, Daniel N Costa, Alberto Diaz De Leon, Marianna Dakanali, Xiankai Sun, Orhan K Oz, Spencer Bowen, Neil M Rofsky, Dana Mathews, Ivan Pedrosa","doi":"10.1186/s41824-025-00268-2","DOIUrl":"10.1186/s41824-025-00268-2","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) will affect approximately 12% of US men in their lifetime and remains the 2nd most common cause of cancer-specific death. However, there is a broad spectrum of severity of PCa; some require aggressive treatment and others can \"watch-and-wait\". Distinction of clinically significant prostate cancer (csPCa) from indolent PCA with current imaging methods remains challenging.</p><p><strong>Objective: </strong>This study aims to evaluate dynamic prostate specific membrane antigen (PSMA) positron emission tomography (PET/CT) in the characterization of suspicious prostate lesions identified on multiparametric MRI (mpMRI).</p><p><strong>Methods: </strong>Prospective study of biopsy-naïve patients with at least one Prostate Imaging and Reporting Data System (PI-RADS) score 5 or one PI-RADS score 4 plus a prostate specific antigen (PSA) ≥ 10 ng/mL. Dynamic PET/CT was performed for 30 min after administration of ⁶⁸Ga Gozetide. Time activity curves (TAC; kBq/cc) of suspicious prostate lesions were generated. TAC logarithmic slope was calculated for each GG at 5-, 10-, 15-, and 30 min. Apparent diffusion coefficient (ADC) at mpMRI for each lesion was tabulated.</p><p><strong>Results: </strong>19 PI-RADS v2.1 ≥ 4 and 6 secondary PI-RADS v2.1 ≥ 3 lesions in 19 patients were analyzed: 4 (16.0%) grade group (GG) 0 (benign), 3 (12.0%) GG 1, 6 (24.0%) GG 2, 6 (24.0%) GG 3, and 6 (24.0%) GG ≥ 4. Significant differences in slope values were observed between clinically insignificant disease (GG 0/1) and GG 2 or higher as early as 5 min post-injection (p < 0.05). At 30 min, GG 1 had the lowest mean slope (- 0.18 ± 0.57) and GG ≥ 4 exhibited the highest mean slope (2.35 ± 2.03). Slope value/ADC ratio further improved discrimination between different GGs.</p><p><strong>Conclusions: </strong>Dynamic ⁶⁸ Ga Gozetotide time activity curves could distinguish GG0/1 from GG3 and GG4/5 PCa. The addition of mpMRI characteristics could further distinguish GG2 from GG4/5. GG2 could not be distinguished from GG3, probably due to small sample size.</p><p><strong>Clinical implications: </strong>Dynamic ⁶⁸ Ga Gozetotide PET/CT imaging may offer enhanced discrimination of MRI-visible prostate cancer lesions and assist in management decisions. Study registered with the FDA (IND 144,177) and clinicaltrials.gov (NCT04179968).</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"35"},"PeriodicalIF":1.7,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145282495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[¹²³I]-mIBG and [¹⁸F]-FDOPA differential uptake in the follow-up of neonatal neuroblastoma.","authors":"Agathe Edet-Sanson, Marine Lechevallier, Romain Modzelewski, Stéphanie Becker, Anne-Charlotte Bouyeure-Petit, Pierre Bohn","doi":"10.1186/s41824-025-00269-1","DOIUrl":"10.1186/s41824-025-00269-1","url":null,"abstract":"<p><p>Single photon emission computed tomography (SPECT/CT) using meta-iodobenzylguanidine (mIBG) is currently recommended in pediatric clinical guidelines for assessing neuroblastoma. However, [¹²³I]-mIBG scintigraphy may sometimes be less sensitive than positron emission tomography/computed tomography (PET/CT) using [¹⁸F]-FDOPA. In order to enhance diagnostic reliability and minimize the risk of missing lesions, both nuclear medicine imaging modalities were used here. We present a case study of a newborn girl who was diagnosed with neuroblastoma in utero. [¹⁸F]-FDOPA PET/CT scans showed faint uptake related to the lesion, whereas [¹²³I]-mIBG scintigraphy was more sensitive and correlated with an MRI-suspicious mass. The metabolic pathways explored by the two tracers are different and sometimes complementary. [¹²³I]-mIBG has an affinity for the norepinephrine transporter, whereas [¹⁸F]-FDOPA has an affinity for the large neutral amino acid transporter-1. The role of [¹⁸F]-FDOPA PET/CT in neuroblastoma is evolving and has been demonstrated to have high sensitivity, but surprisingly, in this particular case, it has limited specificity for neuroblastoma, which was taken into account when interpreting the [¹⁸F]-FDOPA PET/CT scan.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"34"},"PeriodicalIF":0.0,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in clinical neuro-oncology research on integrin PET imaging.","authors":"Dylan Henssen, Siem Herings, Osama Sabri, Swen Hesse, Anja van der Kolk, Anne Arens, Martin Gotthardt","doi":"10.1186/s41824-025-00270-8","DOIUrl":"10.1186/s41824-025-00270-8","url":null,"abstract":"<p><strong>Background: </strong>Angiogenesis plays a pivotal role in the progression of neuro-oncological diseases, mediated by integrin receptors on endothelial and tumor cells. Radiolabeled RGD peptides, targeting integrins such as αvβ₃, offer potential as imaging tracers for diagnosing and monitoring these diseases. This review evaluates the effectiveness and reliability of RGD-containing peptides for PET imaging in neuro-oncology, focusing on diagnostic performance, tumor delineation, and treatment response evaluation.</p><p><strong>Methods: </strong>A systematic literature search was conducted in PubMed, EMBASE, and Cochrane Library until November 2024, identifying relevant studies using RGD-based tracers in neuro-oncological imaging. Data on patient demographics, tumor types, imaging protocols, tracer characteristics, and outcomes were extracted. Methodological quality was assessed using the QUADAS-2 tool.</p><p><strong>Results: </strong>Eight studies, encompassing 112 patients with primary and secondary brain tumors, were included. All studies utilized αvβ₃ integrin expression-targeting RGD PET tracers. Compared to [¹⁸F]FDG PET, RGD-targeted imaging demonstrated superior tumor-to-background ratios, enabling better detection of neuro-oncological lesions. Only a limited number of studies included histopathological validation, which revealed a strong correlation between integrin expression and tracer uptake. RGD-based imaging also predicted treatment response to chemoradiotherapy and bevacizumab, with significant SUVmax reductions linked to better prognoses. No adverse events related to radiotracers were reported. However, since RGD PET tracers do not cross the blood-brain barrier, the extent to which nonspecific accumulation occurs due to blood-brain barrier disruption in neuro-oncological disease remains partially elusive.</p><p><strong>Conclusion: </strong>RGD PET imaging is a promising tool for neuro-oncology, providing enhanced diagnostic accuracy and valuable prognostic insights. Future research should focus on integrating molecular imaging findings into personalized treatment strategies and exploring novel RGD tracers for broader clinical applications.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"33"},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145188227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Right ventricular myocardial blood flow estimated by 13N-ammonia positron emission tomography in patients with coronary artery disease.","authors":"Masateru Kawakubo, Sana Tezuka, Michinobu Nagao, Atsushi Yamamoto, Yoko Kaimoto, Risako Nakao, Yuji Tsutsui, Yuka Matsuo, Koichiro Kaneko, Akiko Sakai, Shuji Sakai","doi":"10.1186/s41824-025-00265-5","DOIUrl":"10.1186/s41824-025-00265-5","url":null,"abstract":"<p><strong>Background: </strong>Because the myocardium thickness and blood flow of the right ventricular (RV) are lower than those of the left ventricle, it is challenging to perceive the RV myocardium in normal individuals. This study aimed to measure the myocardial perfusion in the RV (myocardial blood flow [MBF]_RV, myocardial flow reserve [MFR]_RV) from 13N-ammonia PET images and investigate the associations between the MBF_RV and MFR_RV in patients with and without coronary artery disease (CAD) in the right coronary artery (RCA) region. A total 121 MBF_RV and MFR_RV were retrospectively measured from PET images by referring to the radioactivity and clinical blood flow values of the left ventricle. Adenosine-stressed and resting MBF_RV and MFR_RV were statistically compared among patients with RCA-MFR < 2.0 (group 1 [n = 61]), without RCA-MFR < 2.0 but with reduced MBF (group 2 [n = 16]), and without MFR < 2.0 (group 3 [n = 44]) using one-way analysis of variance with Tukey or Dunn post hoc analyses.</p><p><strong>Results: </strong>Stress MBF_RV was lower in Group 1 than in Group 3, whereas resting MBF_RV was higher in Group 1 than in Group 3. MFR_RV gradually decreased from Group 3 to Group 1.</p><p><strong>Conclusions: </strong>This study demonstrated the potential clinical applications of RV myocardial perfusion imaging using PET data. Our results highlight the importance of evaluating the MBF_RV, particularly in patients with CAD. In CAD cases, the MFR_RV was significantly reduced, with a more pronounced decrease, reflecting the severity of the disease. Additionally, increased resting MBF_RV in patients with CAD may indicate compensatory mechanisms or microcirculatory disorders. These findings provide a foundation for further exploration of MBF_RV and support the development of robust automated processing techniques to enhance clinical applicability.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"32"},"PeriodicalIF":0.0,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12414860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145017132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-molecular imaging showing tumour heterogeneity and differing diagnostic performance in a case with metastatic pheochromocytoma.","authors":"Fredrik Hedeer, Jenny Oddstig, Páll Hallgrimson, Katarina Fagher","doi":"10.1186/s41824-025-00267-3","DOIUrl":"10.1186/s41824-025-00267-3","url":null,"abstract":"<p><p>A patient with multiple endocrine neoplasia 2A (MEN2A) and a suspicion of metastasized pheochromocytoma, underwent multi-molecular positron emission tomography (PET) imaging with the recently presented radiopharmaceutical [¹⁸F]-metafluorobenzylguanidine (mFBG), [⁶⁸Ga]Ga-DOTA-TOC and [¹⁸F]F-dihydroxyphenylalanine (DOPA) as well as scintigraphy with [¹²³I]-metaiodobenzylguanidine (mIBG). The methods showed different diagnostic performance, with the highest number of suspected malignant lesions detected by [¹⁸F]-mFBG-PET, and revealed insights into tumour heterogeneity.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"31"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular imaging techniques in patients with persistent spinal pain syndrome type 2 - a systematic review and meta-analysis.","authors":"Lara S Burmeister, Richard L Witkam, Kris C P Vissers, Martin Gotthardt, Dylan J H A Henssen","doi":"10.1186/s41824-025-00266-4","DOIUrl":"10.1186/s41824-025-00266-4","url":null,"abstract":"<p><p>BACKGROUND: Persistent postoperative low back pain, including persistent spinal pain syndrome type 2 (PSPS-T2), is a global healthcare challenge that lacks objective phenotypic diagnostic criteria or validated biomarkers. Molecular imaging techniques (nuclear medicine) could aid in establishing more objective phenotypical parameters as they are able to visualize biological processes underlying several diseases even before anatomical changes are present. This review aims to provide an overview of the status quo of molecular imaging for the diagnosis of PSPS-T2. METHOD AND RESULTS: An extensive search of PubMed and Embase was conducted to identify relevant studies that comprise imaging techniques using a radiopharmaceutical substance. Evidence reveals that these techniques can provide valuable insights into the underlying pathologies and mechanisms of PSPS-T2 by detecting pain generators that would have otherwise gone unnoticed. Moreover, the meta-analysis showed a pooled sensitivity of 90.3% (95% CI: 53–100%) and a specificity of 89.1% (95% CI: 31–100%) for [18F]NaF PET-CT, and a pooled sensitivity of 61.5% (95% CI: 7–93%) and specificity of 96% (95% CI: 21–100%) for diphosphonates SPECT-CT. CONCLUSION: These findings suggest a potential utility in identifying those who are likely to benefit from surgical re-intervention. This illustrates the potential of molecular imaging in establishing a personalized-medicine approach. However, the retrospective design and the limited sample sizes are among the limitations of the included studies and further research is needed to unravel the potential of molecular imaging techniques as a tool to detect phenotypical biomarkers and to optimize patient care in patients with persistent postoperative low back pain, including PSPS-T2. </p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"30"},"PeriodicalIF":1.7,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}